RTRick Tchamani

Rick Tchamani

*This is an algorithmically generated author record based on publicly available information.

Rick Tchamani has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Human immunodeficiency virus and tuberculosis coinfection prevalence and treatment outcomes in Cameroon: a systematic review and meta-analysis

    by Fabrice Zobel Lekeumo Cheuyem, Rick Tchamani, Arole Darwin Touko, Chabeja Achangwa, Clovis Josué Kachiwouo Mapouo, Germerie Campbell Manfouo Fouodjeu, Ariane Nouko, Saidou Modibo

    Background: Human immunodeficiency virus (HIV) and tuberculosis (TB) form one of the deadliest syndemics, and sub-Saharan Africa bears over 80% of HIV-associated TB deaths. In Cameroon, evidence on HIV/TB coinfection remains unsynthesized across regions and populations, obscuring the national burden. Hence, we estimated the prevalence of HIV/TB coinfection and treatment outcomes in Cameroon. Methods: Following PRISMA 2020 (PROSPERO: CRD420261399169), we searched PubMed, Scopus, Embase, Web of Science, Cochrane Library, African Journals Online, and grey literature for English- and French-language studies conducted in Cameroon. Reports were independently screened, their data extracted, and their methodology appraised using Joanna Briggs Institute tools. Random-effects models pooled prevalence, treatment outcomes, and adjusted odds ratios. Heterogeneity was assessed with I ². Results: Seventy studies (1995–2023) were included, 87.1% at low risk of bias. Pooled HIV prevalence among TB patients was 29.2% (95% CI: 26.3–32.3; 67 studies; n=57,169; I ² = 97.8%), with no significant evidence of publication bias. Prevalence was higher from 2007 onwards (29.9%; 62 studies; n=55,358) than before (20.5%; 5 studies; n=1,811). It was highest in the North-West (41.9%; 7 studies; n=6,324) versus Littoral (25.0%; 15 studies; n=10,419) and West (23.8%; 6 studies; n=4,206); and in extrapulmonary TB (42.3%; 3 studies; n=371) versus mixed forms (37.7%; 21 studies; n=37,239) and pulmonary TB (23.9%; 37 studies; n=16,096) (all p <0.05). Among coinfected patients, pooled treatment success was 75.9% (95% CI: 70.4–80.8; 8 studies; n=4,230), mortality 21.1% (95% CI: 11.9–34.7; 10 studies; n=4,403), loss to follow-up 7.7% (95% CI: 4.3–13.3; 5 studies; n=3,103), and treatment failure 0.3% (95% CI: 0.1–1.5; 6 studies; n=3,520). Lack of antiretroviral therapy (ART) increased the odds of unfavorable outcomes (AOR = 1.90; 95% CI: 1.15–3.12; 2 studies). Conclusions: Approximately three in ten TB patients in Cameroon are coinfected with HIV, with marked regional and clinical variation. Treatment success remains below national targets. Strengthening TB-HIV service integration, routine HIV testing, and timely ART initiation and continuation is essential to reduce the HIV-associated TB morbidity and mortality in the country.

  • Open Access

    Tuberculosis treatment outcome in Cameroon: a systematic review and meta-analysis

    by Fabrice Zobel Lekeumo Cheuyem, Jude Tsafack Zefack, Rick Tchamani, Chabeja Achangwa, Clovis Josué Kachiwouo Mapouo, Armand Tiotsia Tsapi, Claude Axel Minkandi

    Background: Tuberculosis (TB) remains a major public health challenge in Cameroon, yet national evidence on treatment outcomes across the full spectrum of routine care is limited. This systematic review and meta-analysis estimated pooled proportions of treatment success, mortality, treatment failure and loss to follow-up (LTFU) among TB patients in Cameroon, and identified predictors of unfavorable outcomes. Methods: PubMed, Embase, Scopus, Web of Science, African Journals Online and the Cochrane Library were searched, supplemented by Google Scholar and reference-list screening. Observational studies conducted in Cameroon reporting at least one WHO-defined treatment outcome were eligible. Pooled proportions and adjusted odds ratios (AOR) were estimated with random-effects models meta-analysis. Data were analyzed using R Statistics version 4.6.1. Results: Thirty-two studies (25 cohorts, 7 cross-sectional), conducted between 1998 and 2022 across six of Cameroon’s ten regions, were included. Pooled treatment success was 78.2% (95% CI: 73.8–82.1; 27 reports; 71,784 participants; I² = 98.2%), mortality 8.1% (95% CI: 5.5–11.7; 25 reports; 71,870 participants; I² = 97.8%), treatment failure 0.9% (95% CI: 0.5–1.4; 26 reports; 71,389 participants; I² = 89.1%) and LTFU 6.8% (95% CI: 5.0–9.1; 26 reports; 70,768 participants; I² = 98.6%). Mortality was highest in the South-West (16.2%) and among TB/HIV-coinfected patients (30.5%), and lowest among children (5.0%). Treatment success was lowest in the Littoral (71.1%) and among TB/HIV-coinfected patients (60.8%) and highest among multidrug-resistant TB (89.3%) and pediatric patients (86.8%). Treatment failure significantly declined from 2.9% before 2005 to 0.5% from 2020 onward ( p < 0.001). Significant predictors of unfavorable outcomes were HIV positivity (AOR = 2.57; 95% CI: 1.86–3.55), previous TB treatment (AOR = 1.99; 95% CI: 1.40–2.84), male sex (AOR = 1.67; 95% CI: 1.45–1.92), age ≤40 years (AOR = 1.45; 95% CI: 1.06–1.98) and absence of antiretroviral therapy (AOR = 1.71; 95% CI: 1.15–2.54). Conclusions: TB treatment outcomes in Cameroon remain suboptimal, with nearly one in five patients not achieving treatment success and high mortality among TB/HIV-coinfected individuals. Strengthening TB/HIV service integration, early antiretroviral therapy initiation, targeted support for previously treated patients and men, and improved retention in care are needed. Systematic review registration number: CRD420261404490

  • Open Access

    Prevalence of obesity among adults with arterial hypertension in Cameroon: a systematic review and meta-analysis

    by Rick Tchamani, Brian Ngongheh Ajong, Mazou Ngou Temgoua, Arole Darwin Touko, Colince Noupowo Wamba, Eric Brice Touka, Fabrice Zobel Lekeumo Cheuyem

  • Open Access

    Prevalence and factors associated with multidrug resistant Mycobacterium tuberculosis disease in Cameroon: a systematic review and meta-analysis

    by Fabrice Zobel Lekeumo Cheuyem, Chabeja Achangwa, Paul Etoga Mbarga, Rick Tchamani, Solange Dabou, Henri Donald Mutarambirwa, Mazou Ngou Temgoua


  • Open Access

    Vaccine uptake patterns for COVID-19 and cholera among healthcare workers: a cross-sectional study in Yaoundé-Cameroon

    by Ariane Nouko, Fabrice Zobel Lekeumo Cheuyem, Félicitée Nguefack, Rick Tchamani, Innocent Takougang

  • Prevalence of Obesity and Overweight Among Adults Living with Type 2 Diabetes Mellitus in Cameroon: a Systematic Review and Meta-analysis

    by Rick Tchamani, Jude Tsafack Zefack, Doris Bibi Essama, Hadja Inna Astasselbe Abba, Fabrice Zobel Lekeumo Cheuyem

  • Open Access

    Treatment outcomes of drug-resistant Mycobacterium tuberculosis disease in Cameroon: a systematic review and meta-analysis

    by Fabrice Zobel Lekeumo Cheuyem, Arole Darwin Touko, Chabeja Achangwa, Rick Tchamani, Raïssa Katy Noa Otsali, Clovis Josué Kachiwouo Mapouo, Mazou Ngou Temgoua


  • Open Access

    Meningitis vaccination campaign in the context of COVID-19 in Cameroon

    by Marie Angèle Mbang, Adidja Amani, Fabrice Zobel Lekeumo Cheuyem, Rick Tchamani, Collins Asaah Tatang, Aimé Gilbert Mbonda Noula, Christian Nöel Bayiha, Jeudi Debnet, Zacheus Nanje Ebongo, André Arsène Bita Fouda

  • Open Access

    Human papillomavirus vaccine acceptability in Cameroon: a systematic review and meta-analysis

    by Fabrice Zobel Lekeumo Cheuyem, Chabeja Achangwa, Rick Tchamani, Armand Tiotsia Tsapi, Edwige Omona Guissana, Eric Mboke Ekoum, Isabelle Nkwele Mekone

  • Open Access

    Treatment outcomes of drug-resistant Mycobacterium tuberculosis infection in Cameroon: a systematic review and meta-analysis

    by Fabrice Zobel Lekeumo Cheuyem, Arole Darwin Touko, Chabeja Achangwa, Rick Tchamani, Raïssa Katy Noa Otsali, Clovis Josué Kachiwouo Mapouo, Mazou Ngou Temgoua

    Background: Drug-resistant tuberculosis (DR-TB) remains a major challenge to tuberculosis control in sub-Saharan Africa. Cameroon faces substantial challenges in managing DR-TB; however, national evidence on treatment outcomes remains unsynthesized. This systematic review and meta-analysis aimed to estimate pooled treatment outcomes, adverse drug events (ADEs), and predictors of unfavorable outcomes among patients with DR-TB in Cameroon. Methods: This systematic review and meta-analysis followed the PRISMA 2020 guidelines. PubMed, Scopus, Embase, Web of Science, the Cochrane Library, African Journals Online. Google Scholar and reference lists were also searched. Studies reporting World Health Organization-defined treatment outcomes among patients with DR-TB were included. Random-effects meta-analyses using generalized linear mixed models with logit transformation were performed. Heterogeneity was assessed using the I ² statistic, and publication bias and sensitivity analyses were conducted. Results: Fifteen studies conducted between 1998 and 2022 were included. The pooled mortality rate was 6.8% (95% CI: 4.7–9.7; 14 reports; n = 2,351 participants), loss to follow-up was 4.1% (95% CI: 2.8–6.1; 12 studies; n = 2,244 participants), and treatment failure was 5.0% (95% CI: 1.1–19.8; 12 studies; n = 2,050 participants). The pooled treatment success rate was 74.2% (95% CI: 60.4–84.4; 13 reports; n = 2,146 participants). Treatment success improved over time and was higher with modified regimens (87.2%; 95% CI: 83.8–89.9; 3 studies; n = 460 participants) than with standard regimens (68.8%; 95% CI: 52.2–81.6; 10 studies; n = 1,686 participants). Among patients with multidrug-resistant-TB, the pooled prevalence of adverse drug events was 70.8% (95% CI: 40.2–89.7; 3 studies; n = 251 participants), with ototoxicity (41.9%; 95% CI: 23.7–62.6; 3 studies; n = 251 participants) and gastrointestinal disorders (40.9%; 95% CI: 25.5–58.2; 2 studies; n = 172 participants) being the most common events. HIV co-infection was significantly associated with unfavorable treatment outcomes (pooled OR = 2.76; 95% CI: 1.95–3.93; 6 studies), and male gender was also associated with increased odds of unfavorable outcomes (OR = 1.73; 95% CI: 1.25–2.40; 5 studies). Conclusions: Approximately three-quarters of patients with DR-TB in Cameroon achieved successful treatment, although mortality, treatment failure, and adverse drug events remain important concerns. Strengthening pharmacovigilance, integrated TB/HIV care, and the implementation of effective all-oral regimens are essential to improve treatment outcomes. Systematic review registration number: CRD420261404490.